Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Az Threonam
2. Az-threonam
3. Azactam
4. Azthreonam
5. Sq 26,776
6. Sq-26,776
7. Sq26,776
8. Urobactam
1. Azactam
2. 78110-38-0
3. Primbactam
4. Azthreonam
5. Nebactam
6. Azonam
7. Aztreon
8. Rel-aztreonam
9. Sq 26776
10. Sq-26776
11. Nsc646279
12. Chembl158
13. Nsc-646279
14. 149496-40-2
15. Aztreonam E-isomer
16. Nsc-758913
17. 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic Acid
18. Mfcd00072145
19. G2b4ve5gh8
20. Chebi:161680
21. Squibb 26776
22. Sr-01000841814
23. 2-[[(z)-[1-(2-amino-4-thiazolyl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methylpropionic Acid
24. (z)-2-((((2-amino-4-thiazolyl)(((2s,3s)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic Acid
25. Aztreonam (azactam, Cayston)
26. Azetreonam
27. E-aztreonam
28. Prestwick_914
29. Aztreonam [inn]
30. Aztreonam [jan]
31. Aztreonam [mi]
32. Aztreonam [usan]
33. Prestwick2_000185
34. Prestwick3_000185
35. Aztreonam [vandf]
36. Aztreonam [mart.]
37. Aztreonam [usp-rs]
38. Aztreonam [who-dd]
39. Bspbio_000109
40. [2s-[2alpha,3beta(z)]]-2-[[[1-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic Acid
41. Mls003915628
42. Mls006011974
43. Aztreonam, Analytical Standard
44. Bidd:gt0765
45. Bpbio1_000121
46. Aztreonam [orange Book]
47. Dtxsid0022640
48. Aztreonam [usp Monograph]
49. Bcpp000356
50. Hms1568f11
51. Hms2090k09
52. Hms2095f11
53. Hms3712f11
54. Hy-b0129
55. Bdbm50240480
56. Zinc12503091
57. Akos015840157
58. Akos015961777
59. Ac-4330
60. Bcp9000372
61. Ccg-220185
62. Cs-1902
63. Ncgc00179656-01
64. 2-({[(1z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic Acid
65. 2-[(z)-[1-(2-aminothiazol-4-yl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfo-azetidin-3-yl]amino]-2-oxo-ethylidene]amino]oxy-2-methyl-propanoic Acid
66. As-13760
67. Smr002204030
68. Smr004703537
69. So 26776
70. S1505
71. 110a380
72. Sr-01000841814-2
73. Sr-01000841814-3
74. Brd-k62607865-001-03-0
75. Q27262730
76. Aztreonam, United States Pharmacopeia (usp) Reference Standard
77. Aztreonam, Pharmaceutical Secondary Standard; Certified Reference Material
78. (2s,3s)-3-({(2z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate
79. (2s,3s)-3-({(2z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate(aztreonam)
80. 2-((((e)-1-(2-aminothiazol-4-yl)-2-(((2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic Acid
81. 2-((((z)-1-(2-aminothiazol-4-yl)-2-(((2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic Acid
82. 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic Acid
83. 2-[1-(2-amino-thiazol-4-yl)-1-((2s,3s)-2-methyl-4-oxo-1-sulfo-azetidin-3-ylcarbamoyl)-meth-(z)-ylideneaminooxy]-2-methyl-propionic Acid
84. 2-aminothiazol-4-yl)-2-((2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-ylamino)-2-oxoethylideneaminooxy)-2-methylpropanoic Acid
85. 80951-91-3
86. Propanoic Acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2s-(2.alpha.,3.beta.(z)))-
87. Propanoic Acid, 2-[[(z)-[1-(2-amino-4-thiazolyl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methyl-
Molecular Weight | 435.4 g/mol |
---|---|
Molecular Formula | C13H17N5O8S2 |
XLogP3 | 0.3 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 7 |
Exact Mass | 435.05185486 g/mol |
Monoisotopic Mass | 435.05185486 g/mol |
Topological Polar Surface Area | 238 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 808 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 6 | |
---|---|
Drug Name | Azactam |
PubMed Health | Aztreonam (Injection) |
Drug Classes | Antibiotic |
Drug Label | AZACTAM (aztreonam injection) contains the active ingredient aztreonam, a monobactam. It was originally isolated from Chromobacterium violaceum. It is a synthetic bactericidal antibiotic.The monobactams, having a unique monocyclic beta-lactam nucle... |
Active Ingredient | Aztreonam |
Dosage Form | Injectable |
Route | Injection |
Strength | 2gm/vial; 1gm/vial |
Market Status | Prescription |
Company | Bristol Myers Squibb |
2 of 6 | |
---|---|
Drug Name | Aztreonam |
PubMed Health | Aztreonam |
Drug Classes | Antibiotic |
Drug Label | AZACTAM (aztreonam injection) contains the active ingredient aztreonam, a monobactam. It was originally isolated from Chromobacterium violaceum. It is a synthetic bactericidal antibiotic.The monobactams, having a unique monocyclic beta-lactam nucle... |
Active Ingredient | Aztreonam |
Dosage Form | Injectable |
Route | Injection |
Strength | 500mg/vial; 2gm/vial; 1gm/vial |
Market Status | Prescription |
Company | Fresenius Kabi Usa; Eurohlth Intl |
3 of 6 | |
---|---|
Drug Name | Cayston |
PubMed Health | Aztreonam |
Drug Classes | Antibiotic |
Active Ingredient | Aztreonam |
Dosage Form | For solution |
Route | Inhalation |
Strength | 75mg/vial |
Market Status | Prescription |
Company | Gilead |
4 of 6 | |
---|---|
Drug Name | Azactam |
PubMed Health | Aztreonam (Injection) |
Drug Classes | Antibiotic |
Drug Label | AZACTAM (aztreonam injection) contains the active ingredient aztreonam, a monobactam. It was originally isolated from Chromobacterium violaceum. It is a synthetic bactericidal antibiotic.The monobactams, having a unique monocyclic beta-lactam nucle... |
Active Ingredient | Aztreonam |
Dosage Form | Injectable |
Route | Injection |
Strength | 2gm/vial; 1gm/vial |
Market Status | Prescription |
Company | Bristol Myers Squibb |
5 of 6 | |
---|---|
Drug Name | Aztreonam |
PubMed Health | Aztreonam |
Drug Classes | Antibiotic |
Drug Label | AZACTAM (aztreonam injection) contains the active ingredient aztreonam, a monobactam. It was originally isolated from Chromobacterium violaceum. It is a synthetic bactericidal antibiotic.The monobactams, having a unique monocyclic beta-lactam nucle... |
Active Ingredient | Aztreonam |
Dosage Form | Injectable |
Route | Injection |
Strength | 500mg/vial; 2gm/vial; 1gm/vial |
Market Status | Prescription |
Company | Fresenius Kabi Usa; Eurohlth Intl |
6 of 6 | |
---|---|
Drug Name | Cayston |
PubMed Health | Aztreonam |
Drug Classes | Antibiotic |
Active Ingredient | Aztreonam |
Dosage Form | For solution |
Route | Inhalation |
Strength | 75mg/vial |
Market Status | Prescription |
Company | Gilead |
Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Treatment of Gram-negative endobronchial infection in bronchiectasis patients
Treatment of Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J01DF01
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01D - Other beta-lactam antibacterials
J01DF - Monobactams
J01DF01 - Aztreonam
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16751
Submission : 2003-08-08
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-12-24
Pay. Date : 2012-12-03
DMF Number : 19342
Submission : 2006-04-11
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-07-15
Pay. Date : 2013-10-30
DMF Number : 26856
Submission : 2013-10-18
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-07-09
Pay. Date : 2019-05-17
DMF Number : 33731
Submission : 2019-04-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17184
Submission : 2004-02-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38055
Submission : 2023-05-12
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-08-13
Pay. Date : 2019-06-03
DMF Number : 33762
Submission : 2019-04-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20907
Submission : 2007-09-07
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-05-28
Pay. Date : 2013-09-30
DMF Number : 27508
Submission : 2013-09-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23971
Submission : 2010-07-06
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Aztreonam manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aztreonam, including repackagers and relabelers. The FDA regulates Aztreonam manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aztreonam API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Aztreonam manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Aztreonam supplier is an individual or a company that provides Aztreonam active pharmaceutical ingredient (API) or Aztreonam finished formulations upon request. The Aztreonam suppliers may include Aztreonam API manufacturers, exporters, distributors and traders.
click here to find a list of Aztreonam suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Aztreonam DMF (Drug Master File) is a document detailing the whole manufacturing process of Aztreonam active pharmaceutical ingredient (API) in detail. Different forms of Aztreonam DMFs exist exist since differing nations have different regulations, such as Aztreonam USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Aztreonam DMF submitted to regulatory agencies in the US is known as a USDMF. Aztreonam USDMF includes data on Aztreonam's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Aztreonam USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Aztreonam suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Aztreonam Drug Master File in Japan (Aztreonam JDMF) empowers Aztreonam API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Aztreonam JDMF during the approval evaluation for pharmaceutical products. At the time of Aztreonam JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Aztreonam suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Aztreonam as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Aztreonam API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Aztreonam as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Aztreonam and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Aztreonam NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Aztreonam suppliers with NDC on PharmaCompass.
Aztreonam Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aztreonam GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aztreonam GMP manufacturer or Aztreonam GMP API supplier for your needs.
A Aztreonam CoA (Certificate of Analysis) is a formal document that attests to Aztreonam's compliance with Aztreonam specifications and serves as a tool for batch-level quality control.
Aztreonam CoA mostly includes findings from lab analyses of a specific batch. For each Aztreonam CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aztreonam may be tested according to a variety of international standards, such as European Pharmacopoeia (Aztreonam EP), Aztreonam JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aztreonam USP).
LOOKING FOR A SUPPLIER?